New Releases from NCBI BookshelfOsimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection.​Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection.